Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

Cabio Biotech (Wuhan) Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	207.97	153.15	239.68	494.33	664.47	847.32
Trading Asset Securities	-	0.03	0.03	32.8	11.5	13.52
Cash & Short-Term Investments	207.97	153.18	239.71	527.13	675.97	860.84
Cash Growth	-10.28%	-36.10%	-54.53%	-22.02%	-21.48%	1.96%
Accounts Receivable	305.99	285.41	265.64	216.43	178.29	139.29
Other Receivables	10.63	36.39	31.01	40.56	41.08	36.65
Receivables	316.63	321.81	296.65	256.99	219.37	175.94
Inventory	144.52	139.32	112.58	81.49	74.86	65.48
Other Current Assets	52.6	42.36	59.84	41.76	24.66	20.89
Total Current Assets	721.71	656.67	708.78	907.37	994.85	1,123
Property, Plant & Equipment	789.93	767.92	643.28	485.96	241.93	149.51
Long-Term Investments	163.06	191.84	175.37	150.22	117.31	65.93
Other Intangible Assets	42.52	43.09	41.08	36.34	13.15	14.54
Long-Term Deferred Tax Assets	10.44	9.36	11.13	11.49	5.98	6.12
Long-Term Deferred Charges	1.42	1.86	3.67	2.45	0.38	-
Other Long-Term Assets	9.62	16.07	28.18	17.52	74.89	23.59
Total Assets	1,739	1,687	1,611	1,611	1,448	1,383
Accounts Payable	51.91	62.07	70.86	107.34	31.43	24.53
Accrued Expenses	8.68	21.97	15.32	19.15	18.05	17.51
Short-Term Debt	22.59	6.01	11.01	30.03	-	-
Current Portion of Leases	0.51	0.64	1.09	1.35	0.84	-
Current Income Taxes Payable	8.6	5.18	5.86	16.02	5.22	3.59
Current Unearned Revenue	0.32	0.76	2.08	0.43	0.23	2.89
Other Current Liabilities	4.1	5.17	6.2	6.12	4.18	3.79
Total Current Liabilities	96.71	101.79	112.42	180.44	59.95	52.32
Long-Term Debt	29.68	12.63	-	-	-	-
Long-Term Leases	0.02	0.02	0.66	1.66	1.58	-
Long-Term Unearned Revenue	2.63	2.73	4.2	3.66	4.92	6.45
Long-Term Deferred Tax Liabilities	0.09	0.11	0.31	0.54	0.22	0.53
Total Liabilities	129.12	117.27	117.6	186.31	66.68	59.3
Common Stock	168.31	168.31	168.31	120	120	120
Additional Paid-In Capital	811.83	811.83	811.83	858.02	844.82	870.72
Retained Earnings	632.5	587.5	496.95	441.64	416.9	327.92
Treasury Stock	-15.17	-10.82	-	-	-	-
Comprehensive Income & Other	-0.74	-0.74	-0.74	-0.73	-0.69	-0.7
Total Common Equity	1,597	1,556	1,476	1,419	1,381	1,318
Minority Interest	12.85	13.46	17.54	6.1	0.79	5.59
Shareholders' Equity	1,610	1,570	1,494	1,425	1,382	1,324
Total Liabilities & Equity	1,739	1,687	1,611	1,611	1,448	1,383
Total Debt	52.8	19.29	12.76	33.05	2.42	-
Net Cash (Debt)	155.18	133.89	226.95	494.08	673.55	860.84
Net Cash Growth	-29.30%	-41.01%	-54.07%	-26.65%	-21.76%	1.96%
Net Cash Per Share	0.93	0.80	1.34	2.92	4.00	5.13
Filing Date Shares Outstanding	166.65	167.75	168.31	168	168	168
Total Common Shares Outstanding	166.65	167.75	168.31	168	168	168
Working Capital	625	554.88	596.35	726.92	934.9	1,071
Book Value Per Share	9.58	9.28	8.77	8.45	8.22	7.84
Tangible Book Value	1,554	1,513	1,435	1,383	1,368	1,303
Tangible Book Value Per Share	9.33	9.02	8.53	8.23	8.14	7.76
Buildings	-	241.94	241.02	191	94.66	98.57
Machinery	-	636	594.21	529.66	312.24	306.14
Construction In Progress	-	265.55	133.05	49.59	104.18	1.25

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.